The complaint centers on the period between November 25, 2025, and May 4, 2026, during which management repeatedly affirmed optimistic financial targets. Despite Kurdikar describing the company’s pen needle business as "incredibly resolute" at a J.P. Morgan conference in January 2026, the lawsuit contends that internal data revealed softening retail volumes and competitive losses at a major customer. When the true state of the business emerged, the stock price plummeted by $5.35 to $3.90 per share.
In section Releases
Embecta Executives Named in Securities Class Action Lawsuit
A securities class action lawsuit alleges that Embecta Corp. CEO Devdatt Kurdikar and CFO Jacob P. Elguicze disseminated misleading financial guidance throughout early 2026. The litigation claims the executives ignored deteriorating U.S. market conditions, leading to a 57.8% collapse in share price that wiped out significant investor value.
Legal counsel argues that the defendants are liable under Section 20(a) of the Securities Exchange Act as "control persons" who directed public communications. The action highlights that both Kurdikar and Elguicze were required to personally certify the accuracy of financial reports under the Sarbanes-Oxley Act. The court has set August 17, 2026, as the deadline for investors to apply for lead plaintiff status in the ongoing litigation.
Comments (0)
No comments yet. Be the first!